Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 19,645 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 19,645 shares of the business’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20. Following the completion of the sale, the chief financial officer owned 262,954 shares in the company, valued at $7,878,101.84. This represents a 6.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total transaction of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09.

Hims & Hers Health Trading Down 2.7%

Shares of HIMS opened at $28.95 on Thursday. The company’s fifty day moving average is $20.45 and its 200 day moving average is $31.74. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock has a market capitalization of $6.60 billion, a PE ratio of 56.77, a P/E/G ratio of 2.83 and a beta of 2.32. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the previous year, the firm posted $0.11 earnings per share. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Quent Capital LLC purchased a new position in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Silicon Valley Capital Partners purchased a new position in shares of Hims & Hers Health during the third quarter valued at approximately $48,000. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $28,000. Finally, Bogart Wealth LLC boosted its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on HIMS. Evercore set a $24.00 price objective on Hims & Hers Health in a research note on Tuesday, February 24th. Barclays boosted their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 11th. Leerink Partners boosted their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research note on Monday, March 16th. TD Cowen reduced their price objective on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Finally, BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $31.86.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Pipeline & partner speculation — Momentum behind HIMS has been driven by reports of FDA peptide news and a potential partnership with Novo Nordisk, which traders say helped push the stock higher as investors price in new commercial opportunities. Read More.
• Positive Sentiment: Product expansion — HIMS announced it will offer perimenopause/menopause treatment options (including estrogen patch access) on its telehealth platform, expanding addressable market and recurring-care use cases. This is a direct revenue opportunity and supports the company’s DTC care‑platform narrative. Read More.
• Neutral Sentiment: Sector/flow dynamics — Broader small‑cap biotech and telehealth sector enthusiasm (positive clinical results at peers, flow into health names) has amplified HIMS moves even where company‑specific catalysts are limited. That can accelerate swings up or down ahead of earnings. Read More.
• Neutral Sentiment: Analyst & institutional backdrop — Coverage is mixed: consensus is a “Hold” with a mid‑$30s/low‑$20s range of targets and heavy institutional ownership (~63%). Upgrades/target changes have helped sentiment but don’t fully resolve execution risk.
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders have sold sizable blocks recently under pre‑arranged Rule 10b5‑1 plans (April filings). While 10b5‑1 execution mutes signaling, the volume and timing can weigh on near‑term sentiment. Read More. Read More.
• Negative Sentiment: Competitive threat — Amazon’s launch of a GLP‑1 weight‑loss program highlights new, deep-pocketed competition in a key monetizable category for HIMS (weight‑loss/medication access + ongoing care). That announcement pressured the stock amid concerns about margin compression and customer share loss. Read More.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.